7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-3-({1-[2-(2-chloro-3,4-dihydroxybenzamido)ethyl]pyrrolidinium-1-yl}methyl)-3,4-didehydrocepham-4-carboxylic acid (BioDeep_00000851172)
代谢物信息卡片
7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-3-({1-[2-(2-chloro-3,4-dihydroxybenzamido)ethyl]pyrrolidinium-1-yl}methyl)-3,4-didehydrocepham-4-carboxylic acid
化学式: C30H35ClN7O10S2+ (752.1575260000001)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4(CCCC4)CCNC(=O)C5=C(C(=C(C=C5)O)O)Cl)C(=O)O
InChI: InChI=1S/C30H34ClN7O10S2/c1-30(2,28(46)47)48-36-19(16-13-50-29(32)34-16)24(42)35-20-25(43)37-21(27(44)45)14(12-49-26(20)37)11-38(8-3-4-9-38)10-7-33-23(41)15-5-6-17(39)22(40)18(15)31/h5-6,13,20,26H,3-4,7-12H2,1-2H3,(H7-,32,33,34,35,36,39,40,41,42,44,45,46,47)/p+1/t20-,26-/m1/s1
描述信息
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use
同义名列表
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Brent Nishimura, Jenny Escalante, Marisel R Tuttobene, Tomás Subils, Vyanka Mezcord, Camila Pimentel, Nardin Georgeos, Fernando Pasteran, Cecilia Rodriguez, Rodrigo Sieira, Luis A Actis, Marcelo E Tolmasky, Robert A Bonomo, María Soledad Ramirez. Acinetobacter baumannii response to cefiderocol challenge in human urine.
Scientific reports.
2022 05; 12(1):8763. doi:
10.1038/s41598-022-12829-7. [PMID: 35610334] - Nao Kawaguchi, Takayuki Katsube, Roger Echols, Toshihiro Wajima, David P Nicolau. Intrapulmonary Pharmacokinetic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients With Pneumonia and Healthy Subjects.
Journal of clinical pharmacology.
2022 05; 62(5):670-680. doi:
10.1002/jcph.1986. [PMID: 34648652] - Gabriele Bianco, Matteo Boattini, Sara Comini, Roberto Casale, Marco Iannaccone, Rossana Cavallo, Cristina Costa. Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.
2022 Apr; 41(4):573-580. doi:
10.1007/s10096-022-04408-5. [PMID: 35061145] - Eric P Skaar, Roger Echols, Yuko Matsunaga, Anju Menon, Simon Portsmouth. Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP study.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.
2022 Mar; 41(3):467-476. doi:
10.1007/s10096-021-04399-9. [PMID: 35025025] - Muhammad Bilal, Lobna El Tabei, Sören Büsker, Christian Krauss, Uwe Fuhr, Max Taubert. Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol.
Clinical pharmacokinetics.
2021 12; 60(12):1495-1508. doi:
10.1007/s40262-021-01063-5. [PMID: 34420182] - Milo Gatti, Michele Bartoletti, Pier Giorgio Cojutti, Paolo Gaibani, Matteo Conti, Maddalena Giannella, Pierluigi Viale, Federico Pea. A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol.
Journal of global antimicrobial resistance.
2021 12; 27(?):294-298. doi:
10.1016/j.jgar.2021.10.014. [PMID: 34710630] - Luca Borghesi, Valentina Viaggi, Marco Franzetti, Matteo Montoli, Carola Mauri, Giovanni Moioli, Mauro Roberto Benvenuti, Stefania Piconi, Francesco Luzzaro. Successful prolonged cefiderocol treatment of a chronic left pleural empyema caused by Pseudomonas aeruginosa in a patient affected by COVID-19: a case report.
Journal of global antimicrobial resistance.
2021 12; 27(?):157-159. doi:
10.1016/j.jgar.2021.09.005. [PMID: 34562658] - Benoit Llopis, Alexandre Bleibtreu, Dimitri Schlemmer, Pascal Robidou, Olivier Paccoud, Nadine Tissot, Gaëlle Noé, Helga Junot, Charles-Édouard Luyt, Christian Funck-Brentano, Noël Zahr. Simple and accurate quantitative analysis of cefiderocol and ceftobiprole in human plasma using liquid chromatography-isotope dilution tandem mass spectrometry: interest for their therapeutic drug monitoring and pharmacokinetic studies.
Clinical chemistry and laboratory medicine.
2021 10; 59(11):1800-1810. doi:
10.1515/cclm-2021-0423. [PMID: 34243226] - Takayuki Katsube, David P Nicolau, Keith A Rodvold, Richard G Wunderink, Roger Echols, Yuko Matsunaga, Anju Menon, Simon Portsmouth, Toshihiro Wajima. Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia.
The Journal of antimicrobial chemotherapy.
2021 10; 76(11):2902-2905. doi:
10.1093/jac/dkab280. [PMID: 34383901] - Daniel A Hussar. New Drugs 2021, Part 2.
Nursing.
2021 Oct; 51(10):18-29. doi:
10.1097/01.nurse.0000791756.56705.dd. [PMID: 34580258] - Nao Kawaguchi, Takayuki Katsube, Roger Echols, Toshihiro Wajima. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection.
Antimicrobial agents and chemotherapy.
2021 02; 65(3):. doi:
10.1128/aac.01437-20. [PMID: 33257454] - Alessandra Oliva, Giancarlo Ceccarelli, Massimiliano De Angelis, Federica Sacco, Maria Claudia Miele, Claudio M Mastroianni, Mario Venditti. Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii.
Journal of global antimicrobial resistance.
2020 12; 23(?):292-296. doi:
10.1016/j.jgar.2020.09.019. [PMID: 33065329] - Shuhei Matsumoto, Sachi Kanazawa, Takafumi Sato, Yoshinori Yamano. Activities of Cefiderocol with Simulated Human Plasma Concentrations against Carbapenem-Resistant Gram-Negative Bacilli in an In Vitro Chemostat Model.
Antimicrobial agents and chemotherapy.
2020 10; 64(11):. doi:
10.1128/aac.01128-20. [PMID: 32900685] - M W McCarthy. Cefiderocol to treat complicated urinary tract infection.
Drugs of today (Barcelona, Spain : 1998).
2020 Mar; 56(3):177-184. doi:
10.1358/dot.2020.56.3.3118466. [PMID: 32282864] - James M Kidd, Kamilia Abdelraouf, David P Nicolau. Development of Neutropenic Murine Models of Iron Overload and Depletion To Study the Efficacy of Siderophore-Antibiotic Conjugates.
Antimicrobial agents and chemotherapy.
2019 12; 64(1):. doi:
10.1128/aac.01961-19. [PMID: 31658967] - Takayuki Katsube, Roger Echols, Toshihiro Wajima. Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2019 11; 69(Suppl 7):S552-S558. doi:
10.1093/cid/ciz828. [PMID: 31724042] - Rio Nakamura, Tsukasa Ito-Horiyama, Miki Takemura, Shinsuke Toba, Shuhei Matsumoto, Tatsuya Ikehara, Masakatsu Tsuji, Takafumi Sato, Yoshinori Yamano. In Vivo Pharmacodynamic Study of Cefiderocol, a Novel Parenteral Siderophore Cephalosporin, in Murine Thigh and Lung Infection Models.
Antimicrobial agents and chemotherapy.
2019 09; 63(9):. doi:
10.1128/aac.02031-18. [PMID: 31262762] - Carlos Sanabria, Elizabeth Migoya, Jay W Mason, Stephanie H Stanworth, Takayuki Katsube, Mitsuaki Machida, Yukitoshi Narukawa, Tsutae Den Nagata. Effect of Cefiderocol, a Siderophore Cephalosporin, on QT/QTc Interval in Healthy Adult Subjects.
Clinical therapeutics.
2019 09; 41(9):1724-1736.e4. doi:
10.1016/j.clinthera.2019.07.006. [PMID: 31378318] - Takayuki Katsube, Yutaka Saisho, Jingoro Shimada, Hidetoshi Furuie. Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects.
The Journal of antimicrobial chemotherapy.
2019 07; 74(7):1971-1974. doi:
10.1093/jac/dkz123. [PMID: 31220260] - Shiro Miyazaki, Takayuki Katsube, Helen Shen, Charles Tomek, Yukitoshi Narukawa. Metabolism, Excretion, and Pharmacokinetics of [14 C]-Cefiderocol (S-649266), a Siderophore Cephalosporin, in Healthy Subjects Following Intravenous Administration.
Journal of clinical pharmacology.
2019 07; 59(7):958-967. doi:
10.1002/jcph.1386. [PMID: 30730562] - George G Zhanel, Alyssa R Golden, Sheryl Zelenitsky, Karyn Wiebe, Courtney K Lawrence, Heather J Adam, Temilolu Idowu, Ronald Domalaon, Frank Schweizer, Michael A Zhanel, Philippe R S Lagacé-Wiens, Andrew J Walkty, Ayman Noreddin, Joseph P Lynch Iii, James A Karlowsky. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Drugs.
2019 Feb; 79(3):271-289. doi:
10.1007/s40265-019-1055-2. [PMID: 30712199] - Simon Portsmouth, David van Veenhuyzen, Roger Echols, Mitsuaki Machida, Juan Camilo Arjona Ferreira, Mari Ariyasu, Peter Tenke, Tsutae Den Nagata. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
The Lancet. Infectious diseases.
2018 12; 18(12):1319-1328. doi:
10.1016/s1473-3099(18)30554-1. [PMID: 30509675] - Takayuki Katsube, Shiro Miyazaki, Yukitoshi Narukawa, Martha Hernandez-Illas, Toshihiro Wajima. Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters.
European journal of clinical pharmacology.
2018 Jul; 74(7):931-938. doi:
10.1007/s00228-018-2458-9. [PMID: 29627897] - Yutaka Saisho, Takayuki Katsube, Scott White, Hiroyuki Fukase, Jingoro Shimada. Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects.
Antimicrobial agents and chemotherapy.
2018 03; 62(3):. doi:
10.1128/aac.02163-17. [PMID: 29311072] - Nao Kawaguchi, Takayuki Katsube, Roger Echols, Toshihiro Wajima. Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis.
Antimicrobial agents and chemotherapy.
2018 02; 62(2):. doi:
10.1128/aac.01391-17. [PMID: 29038272] - Shuhei Matsumoto, Christine M Singley, Jennifer Hoover, Rio Nakamura, Roger Echols, Stephen Rittenhouse, Masakatsu Tsuji, Yoshinori Yamano. Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics.
Antimicrobial agents and chemotherapy.
2017 09; 61(9):. doi:
10.1128/aac.00700-17. [PMID: 28630178] - Takayuki Katsube, Roger Echols, Juan Camilo Arjona Ferreira, Heidi K Krenz, Jolene Kay Berg, Christopher Galloway. Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects With Renal Impairment.
Journal of clinical pharmacology.
2017 05; 57(5):584-591. doi:
10.1002/jcph.841. [PMID: 27874971] - Takayuki Katsube, Toshihiro Wajima, Toru Ishibashi, Juan Camilo Arjona Ferreira, Roger Echols. Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal Function.
Antimicrobial agents and chemotherapy.
2017 01; 61(1):. doi:
10.1128/aac.01381-16. [PMID: 27795374]